Clinical Research Directory

Inclusion * Females of non-childbearing potential and males \>=18 years of age at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs. * BMI of 18-32 kilogram per meter square(Kg/m\^2); and a total body weight \>50 kg (110 lb). Exclusion * Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention * Prior use of epigenetic modifying agents. Participants will only be permitted to enroll in a single arm of this study (cannot participate in Arm 1 and Arm 2). * Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s). * current use or anticipated need for food or drugs that are known strong inducers or inhibitors of CYP2C9 or CYP3A4, including their administration within 14 days plus 5 half-lives of the strong inducers or inhibitors of CYP2C9 or CYP3A4, whichever is longer, prior to first dose of study intervention, during the treatment period, and within 2 days after the last dose of prifetrastat * Proton pump inhibitors must be discontinued at least 14 days prior to the first dose of study medication and throughout treatment period.